会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • PHENYL-IMIDAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS 5HT3 RECEPTOR ANTAGONISTS
    • 苯并咪唑啉酮衍生物,其制备方法及其作为5HT3受体拮抗剂的用途
    • WO1994011347A1
    • 1994-05-26
    • PCT/EP1993002924
    • 1993-10-22
    • FARMITALIA CARLO ERBA S.R.L.
    • FARMITALIA CARLO ERBA S.R.L.VARASI, MarioHEIDEMPERGHER, FrancoCACCIA, CarlaARRIGONI, Claudio
    • C07D233/61
    • C07D233/64Y02P20/55
    • The invention relates to new derivatives of 1-imidazolylalkyl-3-phenyl-imidazolidin-2-ones of general formula (I), wherein n is 1, 2 or 3; each of R, R1 and R2, which may be the same or different, is hydrogen, halogen, hydroxy, cyano, C1-C6 alkyl, CF3, C1-C6 alkoxy, C1-C6 alkylthio, formyl, C2-C6 alkanoyl, carboxy, C1-C6 alkoxy-carbonyl, nitro, -N(R4 R5) in which each of R4 and R5 independently is hydrogen, C1-C6 alkyl, formyl or C2-C6 alkanoyl; or a (R6 R7)N-SO2 group, in which each of R6 and R7 independently is hydrogen or C1-C6 alkyl; R3 is an imidazolyl group of formula (a) or (b), wherein each of R8 and R10, which may be the same or different, is hydrogen or C1-C6 alkyl, R9 is hydrogen, C1-C6 alkyl or a nitrogen protecting group, or pharmaceutically acceptable salts thereof, which are useful in the treatment of CNS disorders, such as, e.g., anxiety and psychosis, and in the treatment of gut motility disorders, and/or emesis.
    • 本发明涉及通式(I)的1-咪唑基烷基-3-苯基 - 咪唑烷-2-酮的新衍生物,其中n为1,2或3; R,R 1和R 2可以相同或不同,为氢,卤素,羟基,氰基,C 1 -C 6烷基,CF 3,C 1 -C 6烷氧基,C 1 -C 6烷硫基,甲酰基,C 2 -C 6烷酰基,羧基 ,其中R 4和R 5各自独立地为氢,C 1 -C 6烷基,甲酰基或C 2 -C 6烷酰基的C 1 -C 6烷氧羰基,硝基,-N(R 4 R 5) 或(R6R7)N-SO2基团,其中R6和R7各自独立地为氢或C1-C6烷基; R 3是式(a)或(b)的咪唑基,其中R 8和R 10各自可以相同或不同,是氢或C 1 -C 6烷基,R 9是氢,C 1 -C 6烷基或氮保护 组或其药学上可接受的盐,其可用于治疗CNS疾病,例如焦虑和精神病,以及用于治疗肠蠕动障碍和/或呕吐。
    • 6. 发明申请
    • 17'beta'-SUBSTITUTED 4-AZA-5'alpha'-ANDROSTAN-3-ONE DERIVATIVES
    • 17β-取代的4-AZA-5α-二脱氧-3-α衍生物
    • WO1994003476A1
    • 1994-02-17
    • PCT/EP1993002038
    • 1993-07-29
    • FARMITALIA CARLO ERBA S.R.L.
    • FARMITALIA CARLO ERBA S.R.L.PANZERI, AchilleNESI, MarcellaDI SALLE, Enrico
    • C07J73/00
    • C07J73/005
    • A compound of formula (I), wherein R is a hydrogen atom or a C1-C4 alkyl group; A is a single bond or a straight or branched C1-C6 alkylene chain; R1 is a hydrogen atom or a C1-C6 alkyl group; R2 is a C1-C6 alkyl group, a C5-C7 cycloalkyl or a C6-C10 cycloalkylalkyl group, aryl or a C7-C10 arylalkyl group, or a C6-C10 heterocycloalkyl group; R3 is hydrogen, a C1-C4 alkyl group or an aryl or a C7-C10 arylalkyl group; Z is a C1-C6 alkyl group, an -OR5 group wherein R5 is a C1-C6 alkyl group, a (a) group wherein each of R6 and R7 is hydrogen, C1-C6 alkyl, C5-C7 cycloalkyl, phenyl or R6 and R7 taken together with the nitrogen to which they are linked form a pentatomic or hexatomic saturated heteromonocyclic ring; and the symbol .Ÿ .Ÿ .Ÿ .Ÿ represents a single or a double bond, is a testosterone 5(alpha)-reductase inhibitor and is therapeutically useful in benign prostatic hyperplasia, prostatic and breast cancers, seborrhoea, female hirsutism and male pattern baldness.
    • 式(I)的化合物,其中R是氢原子或C1-C4烷基; A是单键或直链或支链C1-C6亚烷基链; R1是氢原子或C1-C6烷基; R2是C1-C6烷基,C5-C7环烷基或C6-C10环烷基烷基,芳基或C7-C10芳基烷基或C6-C10杂环烷基; R3是氢,C1-C4烷基或芳基或C7-C10芳烷基; Z是C1-C6烷基,其中R5是C1-C6烷基的-OR5基团,其中R6和R7各自为氢,C1-C6烷基,C5-C7环烷基,苯基或R6 和R7与它们所连接的氮原子一起形成五原子或六原子饱和杂单环; 和符号.Ÿ.Ÿ。表示单键或双键,是睾酮5(α) - 还原酶抑制剂,可用于良性前列腺增生,前列腺和乳腺癌,皮脂溢,女性多毛症和雄性模式 秃顶。
    • 10. 发明申请
    • REDUCED IRREVERSIBLE BOMBESIN ANTAGONISTS
    • 减少不可逆的BOMBESIN ANTAGONISTS
    • WO1991006563A1
    • 1991-05-16
    • PCT/EP1990001836
    • 1990-11-02
    • FARMITALIA CARLO ERBA S.R.L.DE CASTIGLIONE, RobertoGOZZINI, LuigiaCORRADI, FabioCIOMEI, MarinaMOLINARI, IsabellaFRANZETTI, Cristina
    • FARMITALIA CARLO ERBA S.R.L.
    • C07K07/02
    • C07K7/086A61K38/00
    • A peptide of the formula (I): R-A-B-C-Trp-Ala-Val-X-Y-T-W, wherein R represents a group of the formula 4-(ClCH2CH2)2N-C6H4-CH2CH(NHR1)CO-; 3-(ClCH2CH2)2N-C6H4-CH2CH(NHR1)CO-; 4-(ClCH2CH2)2N-C6H4-CO-; 3-(ClCH2CH2)2N-C6H4-CO-; ClCH2CH2NHCO-; ClCH=CH-CO-, BrCH=CH-CO-, CH2=CClCO-, CH2=CBrCO- (either cis or trans isomers); (a); CH=C-CO-; ClCH2CH2CH2N(NO)CO-; ClCH2CO-CH(R2)NHCO(CH2)2CO-; A represents a valence bond, or a Gly, Leu-Gly, Arg-Leu-Gly, or Gln-Arg-Leu-Gly residue, B represents a valence bond or a Asn, Phe or Thr residue; C represents a Gln or His residue, X represents a Gly or ala residue; Y represents a valence bond, or a His(R3), his(R3), Phe, phe, Ser, ser, Ala or ala residue; T represents a valence bond, or a Leu, leu, Phe or phe residue; W represents a group of the formula OR2, NH2, NH(CH2)4)CH3, NH(CH2)2C6H5, Met-R4, Leu-R4, Ile-R4 or Nle-R4; R1 represents a hydrogen atom, a Boc group or an acyl group, R2 represents a hydrogen atom, a linear or branched alyphatic chain having from 1 to 11 carbon atoms, a benzyl or a C1-C21 phenyl group, R3 represents a hydrogen atom or a Tos, Dnp or Bzl group, R4 represents NH2, NH-NH2 or OR2, one or more peptide bonds (CONH) are replaced by reduced peptide bonds (CH2, NH), and the pharmaceutically acceptable salts thereof and pharmaceutically acceptable salts are bombesin antagonists. Their preparation and pharmaceutical compositions containing them are also described.
    • 式(I)的肽:R-A-B-C-Trp-Ala-Val-X-Y-T-W,其中R表示式4-(ClCH 2 CH 2)2 N-C 6 H 4 -CH 2 CH(NHR 1)CO-; 3-(ClCH2CH2)2 N-C 6 H 4 CH 2 CH(NHR 1)CO-; 4-(ClCH2CH2)2 N-C6H4-CO-; 3-(ClCH2CH2)2 N-C6H4-CO-; ClCH2CH2NHCO-; ClCH = CH-CO-,BrCH = CH-CO-,CH2 = CClCO-,CH2 = CBrCO-(顺式或反式异构体); (一个); CH = C-CO-; ClCH2CH2CH2N(NO)CO-; ClCH2CO-CH(R2)NHCO(CH 2)2 CO-; A表示价键,或Gly,Leu-Gly,Arg-Leu-Gly或Gln-Arg-Leu-Gly残基,B表示价键或Asn,Phe或Thr残基; C表示Gln或His残基,X表示Gly或ala残基; Y代价键,或His(R3),他的(R3),Phe,phe,Ser,ser,Ala或ala残基; T表示价键,或Leu,leu,Phe或phe残基; W表示式OR2,NH2,NH(CH2)4)CH3,NH(CH2)2C6H5,Met-R4,Leu-R4,Ile-R4或Nle-R4的基团; R 1表示氢原子,Boc基或酰基,R 2表示氢原子,具有1至11个碳原子的直链或支链亚构链,苄基或C 1 -C 21苯基,R 3表示氢原子或 Tos,Dnp或Bzl基团,R4代表NH2,NH-NH2或OR2,一个或多个肽键(CONH)被还原的肽键(CH2,NH)取代,其药学上可接受的盐和药学上可接受的盐是铃蟾肽 拮抗剂。 还描述了它们的制备方法和含有它们的药物组合物。